<unk>  is both a substrate and an inhibitor of P-glycoprotein (P-gp) and CYP3A4. Hence P-gp and CYP3A4 inhibitors may increase plasma levels of<unk> . Likewise CYP3A4 inducers may reduce plasma concentrations of<unk> . It may also alter the metabolism and uptake (into the GIT by means of its P-gp inhibitory effects) of other drugs that are substrates for P-gp and CYP3A4. WEE1 kinase domain in complex with<unk> .
Bosutinib
Ibrutinib
Imatinib
Acalabrutinib
Ponatinib
Afatinib
Ceritinib
Ruxolitinib